7UY1
HUMAN PRMT5:MEP50 COMPLEX WITH MTA and Fragment 5 Bound
Summary for 7UY1
| Entry DOI | 10.2210/pdb7uy1/pdb |
| Descriptor | Protein arginine N-methyltransferase 5, Methylosome protein 50, 3-methyl-1,5-naphthyridin-2-amine, ... (9 entities in total) |
| Functional Keywords | mtap, methyl transferase, fragment-based lead discovery, fbdd, transferase |
| Biological source | Homo sapiens (human) More |
| Total number of polymer chains | 2 |
| Total formula weight | 112692.02 |
| Authors | Gunn, R.J. (deposition date: 2022-05-06, release date: 2022-10-05, Last modification date: 2024-05-22) |
| Primary citation | Smith, C.R.,Kulyk, S.,Ahmad, M.U.D.,Arkhipova, V.,Christensen, J.G.,Gunn, R.J.,Ivetac, A.,Ketcham, J.M.,Kuehler, J.,Lawson, J.D.,Thomas, N.C.,Wang, X.,Marx, M.A. Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits. Rsc Med Chem, 13:1549-1564, 2022 Cited by PubMed Abstract: Here we describe the early stages of a fragment-based lead discovery (FBLD) project for a recently elucidated synthetic lethal target, the PRMT5/MTA complex, for the treatment of -deleted cancers. Starting with five fragment/PRMT5/MTA X-ray co-crystal structures, we employed a two-phase fragment elaboration process encompassing optimization of fragment hits and subsequent fragment growth to increase potency, assess synthetic tractability, and enable structure-based drug design. Two lead series were identified, one of which led to the discovery of the clinical candidate MRTX1719. PubMed: 36545438DOI: 10.1039/d2md00163b PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.66 Å) |
Structure validation
Download full validation report
